Corgenix Announces Issuance of Additional U.S. Patent for AspirinWorks® (11-dehydro Thromboxane B2) Test

Patent strengthens intellectual property portfolio, enhances competitive position

DENVER — May 29, 2012— Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks ® technology. The U.S. Patent and Trademark Office has issued U.S. Patent No. 8,168,400 on the AspirinWorks Test Kit, which measures thromboxane metabolites in urine to evaluate aspirin effect in apparently healthy individuals. The composition-of-matter claims provide intellectual property coverage for the monoclonal antibody that recognizes thromboxane metabolites.

“This patent increases the scope and variety of claims on the AspirinWorks Test Kit,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “By further protecting the AspirinWorks Test we’re strengthening our intellectual property portfolio and enhancing our competitive position in the clinical testing market.”

Corgenix was previously issued a U.S. Patent in 2010 related to the AspirinWorks Test’s ability to more accurately depict true levels of circulating thromboxane metabolites, chemicals that activate blood platelets and cause them to stick together. Aspirin is widely prescribed as an antiplatelet drug because of its ability to inhibit thromboxane formation and help prevent ischemic events such as heart attack and stroke.

More than 1 million Americans experience new or recurrent heart attacks each year. At-risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy’s effect. AspirinWorks is the only FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals post ingestion. 11dhTxB2 is a metabolite of thromboxane A2 (TxA2), the target of aspirin therapy. The test targets a potential global market exceeding 200 million individuals.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail More information is also available at

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, which are inherently uncertain, are based on management’s current expectations and are subject to various factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission, and in the Company’s subsequent filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation or intend to publicly update or revise any forward-looking statements.


Corgenix Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP Operations and Finance, CFO
Phone: 303-453-8903


Corgenix Media Contact:

Dan Snyders
Vice President and Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230
Fax: 303-623-1191